Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10360439 | 0.93 | GNAI3 (0.33) | HRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL10176085 | 0.86 | CHRNB2 (0.36) | HRH3 | |
| SCHEMBL21210559 | 0.86 | CHRNB2 (0.36) | HRH3 | |
| SCHEMBL12209130 | 0.86 | CHRNB2 (0.32) | HRH3 | |
| SCHEMBL21786928 | 0.86 | CHRNB2 (0.32) | HRH3 | |
| SCHEMBL22317563 | 0.82 | HRH3 (0.35) | HRH3 | |
| SCHEMBL19934380 | 0.82 | GNAI3 (0.36) | GNAI3GNAO1GNAI1 | |
| SCHEMBL17694861 | 0.80 | HRH3 (0.33) | HRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL17694859 | 0.80 | CCR5 (0.36) | HRH3 | |
| SCHEMBL3996073 | 0.78 | GNAI3 (0.42) | HRH3GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796701-B2 | Kinase inhibitor and use thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-10-24 | — | — | US | disclosed |
| US-8993535-B2 | Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120184505-A1 | MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184505-A1 | MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CDC25A, CDC25B | HRH3 3532/4885GNAI3 1970/4885GNAO1 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.